Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Belgium / NCT07557771
Recruiting Not applicable

Wideband Tympanometry as a Non-behavioral Test of the Speech-weighted Middle Ear Transfer Function.

NCT07557771 · tracked via the Priya Life Science Belgium tracker
Sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Not applicable
Started
2025-07-04
Last updated
2026-04-29

Condition(s) studied

Conductive Hearing Loss

Investigational drug(s) / intervention(s)

Wideband Tympanometry

Wideband Tympanometry: Wideband Tympanometry evaluates the condition of the middle ear by measuring the middle ear's acoustic response in function of pressure and frequency. To this end, a probe containing a speaker, microphone and pressure pomp is gently inserted into the external ear canal. Tests are performed with a CE approved device.

Study summary

There is a need for a non-behavioral clinical test that provides an assessment of how speech is conducted through the middle ear for the optimization of middle ear implants. These implants utilize the functionality of the human middle ear and require adequate speech conduction through the middle ear chain. Consequently, the clinical test of this degree of speech transfer can contribute to the pre-operative indication for middle ear implants.

Wideband Tympanometry (WT) is a non-invasive diagnostic tool for the clinical assessment of the condition of the middle ear. Unlike classical tympanometry, WT tests the impedance of the middle ear system as a function of both pressure and frequencies. Consequently, a WT measurement contains many times more information about the functionality of the middle ear than classical tympanometry and is ideally suited as a diagnostic tool for the clinical assessment of speech transfer through the middle ear. The WT measurements will be correlated with the Speech Intelligibility Index (SII) collected in normally hearing individuals and patients with isolated conductive hearing loss. This index is a measure of speech transfer through the middle ear. Consequently, a correlation of the WT measurements with the SII addresses the need for a non-behavioral clinical test of speech transfer through the middle ear.

Additionally, WT measurements will be performed longitudinally in cochlear implant candidates, one of the populations that can benefit from the developed clinical test. These longitudinal WT measurements, which will be performed both pre- and post-operatively, allow for the evaluation of the impact of middle ear surgery on the predicted SII.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * NH subjects * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures. * At least 18 years of age at the time of signing the ICF. * Pure tone audiometry: * Air-conduction hearing threshold at all frequencies ≤15dB. * No air-bone-gap. * Normal classical tympanometry: Jerger A (see fig. 1) * CHL subjects * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures. * At least 18 years of age at the time of signing the ICF. * Pure tone audiometry: * Bone-conduction threshold at all frequencies ≤20dB. * Two exceptions: * Age-related hearing loss: bone-conduction threshold ≤40dB in the higher frequencies (\> 2kHz). * Carhart notch: bone-conduction threshold \>20dB around 2kHz. air-bone-gap ≥10dB at ≥ 1 frequency. * CI recipients * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures. * At least 18 years of age at the time of signing the ICF. * Ear is planned for CI surgery by treating ENT surgeon. * Normal classical tympanometry: Jerger A. Exclusion Criteria * NH subjects * Patient has history of extensive middle ear disease. * Patient has history of middle ear surgery. * Abnormal otoscopy showing signs of tympanic membrane perforation or middle ear effusion. * Severe otitis externa or occlusion of the external auditory canal * Participation in an interventional Trial with an investigational medicinal product (IMP) or device * CHL subjects * Patient has history of middle ear surgery. * Abnormal otoscopy showing signs of tympanic membrane perforation or middle ear effusion. * Signs of structural pathological processes such as tumors, cysts or cholesteatoma. * Severe otitis externa or occlusion of the external auditory canal * Participation in an interventional Trial with an investigational medicinal product (IMP) or device * CI recipients * ear has history of extensive middle ear disease. * ear has history of middle ear surgery. * Abnormal otoscopy showing signs of tympanic membrane perforation or middle ear effusion. * Severe otitis externa or occlusion of the external auditory canal

Primary outcome measure(s)

  • Wideband Absorbance as measured with Wideband Tympanometry — 5 minutes
    Wideband Absorbance in function of frequency and pressure, as measured with Wideband Tympanometry. The device used is the Titan (interacoustics, Denmark). Frequency resolution is 503 logarithmically spaced frequency bins ranging from 226Hz up to 12000Hz and pressure points resolution depends on the sweep speed but varies between 200 and 210 points, equally spaced between -600daPa en +300daPa.

Trial sites (1)

FacilityCityRegionStatus
UZ Leuven Leuven Belgium Recruiting

More Universitaire Ziekenhuizen KU Leuven trials in Belgium

Pilot Study on Muscle, Tendon, and Neural Changes Post-Botulinum Toxin Injections in Post-stroke Spastic Equinovarus Recruiting
Pediatric Eosinophilic Esophagitis (pedEoE): Effect of Allergen Heat Denaturation on EoE Remission: a Pilot Trial Recruiting
Improving the Use of Immunotherapy to Treat Liver Cancer Recruiting
EUS-guided Response Assessment to NSBB Recruiting
[18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07557771 on ClinicalTrials.gov ↗ ← All trials in Belgium